YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer
Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with par...
Gespeichert in:
Veröffentlicht in: | The EMBO journal 2023-07, Vol.42 (14), p.e112614-n/a |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 14 |
container_start_page | e112614 |
container_title | The EMBO journal |
container_volume | 42 |
creator | Yamazaki, Masaya Hino, Shinjiro Usuki, Shingo Miyazaki, Yoshihiro Oda, Tatsuya Nakao, Mitsuyoshi Ito, Takaaki Yamagata, Kazuya |
description | Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability.
Synopsis
Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC.
Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1.
Intratumoral ROR1
high
cells are tumor‐initiating cells with increased tumorigenic capacity.
ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis.
ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation.
ROR1
transcription is dependent on the YAP/BRD4 axis.
Graphical Abstract
ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling. |
doi_str_mv | 10.15252/embj.2022112614 |
format | Article |
fullrecord | <record><control><sourceid>proquest_C6C</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10350825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2806073657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS1ERYfCnhWyxIZN2msndlIJCbWlQFFR0QgWrCzHPzMeJXZqJ1Sz6yPwjDwJbqc_FAmxsn39naNzdBF6QWCXMMronunb1S4FSgmhnFSP0IxUHAoKNXuMZpBnRUWa_W30NKUVALCmJk_QdlnDPucNmaHl94Mve4fzd9Wvy58q-DGGrjMaz8_mBA8x9GE0CY9TH2IGnHejk6PzC6xM1yUsvcbL9WBiRjtnTcyfwWPn8SC9iiY_FVb5auIztGVll8zzm3MHfXt__PXoY3F69uHk6OC0UIxCVTRKa5rjt7RWVWlZqSjXwKzlugWpAWxracVLTZglJRjQhjFaU6VlRVQe7aC3G99hanujlcmdZCeG6HoZ1yJIJx7-eLcUi_BDECgZNJRlh9c3DjGcTyaNonfpqq_0JkxJ0AY41CVndUZf_YWuwhR97pepsiF1STlkCjaUiiGlaOxdGgLieo_iao_ifo9Z8vLPFneC28Vl4M0GuHCdWf_XUBx_Pvz0wJ9s5Ckr_cLE--D_zPQbrlK92Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2838173260</pqid></control><display><type>article</type><title>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</title><source>Springer Nature OA Free Journals</source><creator>Yamazaki, Masaya ; Hino, Shinjiro ; Usuki, Shingo ; Miyazaki, Yoshihiro ; Oda, Tatsuya ; Nakao, Mitsuyoshi ; Ito, Takaaki ; Yamagata, Kazuya</creator><creatorcontrib>Yamazaki, Masaya ; Hino, Shinjiro ; Usuki, Shingo ; Miyazaki, Yoshihiro ; Oda, Tatsuya ; Nakao, Mitsuyoshi ; Ito, Takaaki ; Yamagata, Kazuya</creatorcontrib><description>Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability.
Synopsis
Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC.
Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1.
Intratumoral ROR1
high
cells are tumor‐initiating cells with increased tumorigenic capacity.
ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis.
ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation.
ROR1
transcription is dependent on the YAP/BRD4 axis.
Graphical Abstract
ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.</description><identifier>ISSN: 0261-4189</identifier><identifier>EISSN: 1460-2075</identifier><identifier>DOI: 10.15252/embj.2022112614</identifier><identifier>PMID: 37096681</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adenocarcinoma ; AKT protein ; AURKB ; Aurora kinase ; BRD4 ; Cancer ; Cancer therapies ; Carcinoma, Pancreatic Ductal - genetics ; Cell Cycle Proteins - metabolism ; Cell Line, Tumor ; Cell Proliferation ; Chemoresistance ; Chemotherapy ; E2F protein ; EMBO03 ; Epithelial-Mesenchymal Transition ; Gene Expression Regulation, Neoplastic ; Gene sequencing ; Humans ; Kinases ; Life Sciences ; Metastases ; Metastasis ; Myc protein ; Nuclear Proteins - metabolism ; pancreatic adenocarcinoma ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - metabolism ; Protein-tyrosine kinase receptors ; Receptor Tyrosine Kinase-like Orphan Receptors - genetics ; Receptor Tyrosine Kinase-like Orphan Receptors - metabolism ; Receptors ; ROR1 ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Tumor cells ; Tumors ; tumor‐initiating cells ; Tyrosine ; Yes-associated protein</subject><ispartof>The EMBO journal, 2023-07, Vol.42 (14), p.e112614-n/a</ispartof><rights>The Author(s) 2023</rights><rights>2023 The Authors</rights><rights>2023 The Authors.</rights><rights>2023 EMBO</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</citedby><cites>FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</cites><orcidid>0000-0002-5748-016X ; 0000-0003-4151-4983 ; 0000-0002-9959-3322 ; 0000-0002-2196-8673 ; 0000-0001-5528-3464 ; 0000-0001-7564-7579</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350825/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350825/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,41096,42165,45550,45551,46384,46808,51551,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://doi.org/10.15252/embj.2022112614$$EView_record_in_Springer_Nature$$FView_record_in_$$GSpringer_Nature</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37096681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamazaki, Masaya</creatorcontrib><creatorcontrib>Hino, Shinjiro</creatorcontrib><creatorcontrib>Usuki, Shingo</creatorcontrib><creatorcontrib>Miyazaki, Yoshihiro</creatorcontrib><creatorcontrib>Oda, Tatsuya</creatorcontrib><creatorcontrib>Nakao, Mitsuyoshi</creatorcontrib><creatorcontrib>Ito, Takaaki</creatorcontrib><creatorcontrib>Yamagata, Kazuya</creatorcontrib><title>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</title><title>The EMBO journal</title><addtitle>EMBO J</addtitle><addtitle>EMBO J</addtitle><description>Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability.
Synopsis
Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC.
Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1.
Intratumoral ROR1
high
cells are tumor‐initiating cells with increased tumorigenic capacity.
ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis.
ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation.
ROR1
transcription is dependent on the YAP/BRD4 axis.
Graphical Abstract
ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.</description><subject>Adenocarcinoma</subject><subject>AKT protein</subject><subject>AURKB</subject><subject>Aurora kinase</subject><subject>BRD4</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Pancreatic Ductal - genetics</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>E2F protein</subject><subject>EMBO03</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene sequencing</subject><subject>Humans</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Myc protein</subject><subject>Nuclear Proteins - metabolism</subject><subject>pancreatic adenocarcinoma</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Protein-tyrosine kinase receptors</subject><subject>Receptor Tyrosine Kinase-like Orphan Receptors - genetics</subject><subject>Receptor Tyrosine Kinase-like Orphan Receptors - metabolism</subject><subject>Receptors</subject><subject>ROR1</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>tumor‐initiating cells</subject><subject>Tyrosine</subject><subject>Yes-associated protein</subject><issn>0261-4189</issn><issn>1460-2075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS1ERYfCnhWyxIZN2msndlIJCbWlQFFR0QgWrCzHPzMeJXZqJ1Sz6yPwjDwJbqc_FAmxsn39naNzdBF6QWCXMMronunb1S4FSgmhnFSP0IxUHAoKNXuMZpBnRUWa_W30NKUVALCmJk_QdlnDPucNmaHl94Mve4fzd9Wvy58q-DGGrjMaz8_mBA8x9GE0CY9TH2IGnHejk6PzC6xM1yUsvcbL9WBiRjtnTcyfwWPn8SC9iiY_FVb5auIztGVll8zzm3MHfXt__PXoY3F69uHk6OC0UIxCVTRKa5rjt7RWVWlZqSjXwKzlugWpAWxracVLTZglJRjQhjFaU6VlRVQe7aC3G99hanujlcmdZCeG6HoZ1yJIJx7-eLcUi_BDECgZNJRlh9c3DjGcTyaNonfpqq_0JkxJ0AY41CVndUZf_YWuwhR97pepsiF1STlkCjaUiiGlaOxdGgLieo_iao_ifo9Z8vLPFneC28Vl4M0GuHCdWf_XUBx_Pvz0wJ9s5Ckr_cLE--D_zPQbrlK92Q</recordid><startdate>20230717</startdate><enddate>20230717</enddate><creator>Yamazaki, Masaya</creator><creator>Hino, Shinjiro</creator><creator>Usuki, Shingo</creator><creator>Miyazaki, Yoshihiro</creator><creator>Oda, Tatsuya</creator><creator>Nakao, Mitsuyoshi</creator><creator>Ito, Takaaki</creator><creator>Yamagata, Kazuya</creator><general>Nature Publishing Group UK</general><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5748-016X</orcidid><orcidid>https://orcid.org/0000-0003-4151-4983</orcidid><orcidid>https://orcid.org/0000-0002-9959-3322</orcidid><orcidid>https://orcid.org/0000-0002-2196-8673</orcidid><orcidid>https://orcid.org/0000-0001-5528-3464</orcidid><orcidid>https://orcid.org/0000-0001-7564-7579</orcidid></search><sort><creationdate>20230717</creationdate><title>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</title><author>Yamazaki, Masaya ; Hino, Shinjiro ; Usuki, Shingo ; Miyazaki, Yoshihiro ; Oda, Tatsuya ; Nakao, Mitsuyoshi ; Ito, Takaaki ; Yamagata, Kazuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>AKT protein</topic><topic>AURKB</topic><topic>Aurora kinase</topic><topic>BRD4</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Pancreatic Ductal - genetics</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>E2F protein</topic><topic>EMBO03</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene sequencing</topic><topic>Humans</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Myc protein</topic><topic>Nuclear Proteins - metabolism</topic><topic>pancreatic adenocarcinoma</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Protein-tyrosine kinase receptors</topic><topic>Receptor Tyrosine Kinase-like Orphan Receptors - genetics</topic><topic>Receptor Tyrosine Kinase-like Orphan Receptors - metabolism</topic><topic>Receptors</topic><topic>ROR1</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>tumor‐initiating cells</topic><topic>Tyrosine</topic><topic>Yes-associated protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamazaki, Masaya</creatorcontrib><creatorcontrib>Hino, Shinjiro</creatorcontrib><creatorcontrib>Usuki, Shingo</creatorcontrib><creatorcontrib>Miyazaki, Yoshihiro</creatorcontrib><creatorcontrib>Oda, Tatsuya</creatorcontrib><creatorcontrib>Nakao, Mitsuyoshi</creatorcontrib><creatorcontrib>Ito, Takaaki</creatorcontrib><creatorcontrib>Yamagata, Kazuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The EMBO journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Yamazaki, Masaya</au><au>Hino, Shinjiro</au><au>Usuki, Shingo</au><au>Miyazaki, Yoshihiro</au><au>Oda, Tatsuya</au><au>Nakao, Mitsuyoshi</au><au>Ito, Takaaki</au><au>Yamagata, Kazuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</atitle><jtitle>The EMBO journal</jtitle><stitle>EMBO J</stitle><addtitle>EMBO J</addtitle><date>2023-07-17</date><risdate>2023</risdate><volume>42</volume><issue>14</issue><spage>e112614</spage><epage>n/a</epage><pages>e112614-n/a</pages><issn>0261-4189</issn><eissn>1460-2075</eissn><abstract>Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability.
Synopsis
Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC.
Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1.
Intratumoral ROR1
high
cells are tumor‐initiating cells with increased tumorigenic capacity.
ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis.
ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation.
ROR1
transcription is dependent on the YAP/BRD4 axis.
Graphical Abstract
ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37096681</pmid><doi>10.15252/embj.2022112614</doi><tpages>32</tpages><orcidid>https://orcid.org/0000-0002-5748-016X</orcidid><orcidid>https://orcid.org/0000-0003-4151-4983</orcidid><orcidid>https://orcid.org/0000-0002-9959-3322</orcidid><orcidid>https://orcid.org/0000-0002-2196-8673</orcidid><orcidid>https://orcid.org/0000-0001-5528-3464</orcidid><orcidid>https://orcid.org/0000-0001-7564-7579</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 0261-4189 |
ispartof | The EMBO journal, 2023-07, Vol.42 (14), p.e112614-n/a |
issn | 0261-4189 1460-2075 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10350825 |
source | Springer Nature OA Free Journals |
subjects | Adenocarcinoma AKT protein AURKB Aurora kinase BRD4 Cancer Cancer therapies Carcinoma, Pancreatic Ductal - genetics Cell Cycle Proteins - metabolism Cell Line, Tumor Cell Proliferation Chemoresistance Chemotherapy E2F protein EMBO03 Epithelial-Mesenchymal Transition Gene Expression Regulation, Neoplastic Gene sequencing Humans Kinases Life Sciences Metastases Metastasis Myc protein Nuclear Proteins - metabolism pancreatic adenocarcinoma Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - metabolism Protein-tyrosine kinase receptors Receptor Tyrosine Kinase-like Orphan Receptors - genetics Receptor Tyrosine Kinase-like Orphan Receptors - metabolism Receptors ROR1 Transcription Factors - genetics Transcription Factors - metabolism Tumor cells Tumors tumor‐initiating cells Tyrosine Yes-associated protein |
title | YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_C6C&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=YAP/BRD4%E2%80%90controlled%20ROR1%20promotes%20tumor%E2%80%90initiating%20cells%20and%20hyperproliferation%20in%20pancreatic%20cancer&rft.jtitle=The%20EMBO%20journal&rft.au=Yamazaki,%20Masaya&rft.date=2023-07-17&rft.volume=42&rft.issue=14&rft.spage=e112614&rft.epage=n/a&rft.pages=e112614-n/a&rft.issn=0261-4189&rft.eissn=1460-2075&rft_id=info:doi/10.15252/embj.2022112614&rft_dat=%3Cproquest_C6C%3E2806073657%3C/proquest_C6C%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2838173260&rft_id=info:pmid/37096681&rfr_iscdi=true |